# Title: Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors

# Running Title: COVID-19 seroprevalence and hematimetry

Author names and affiliations:

M Carmen Martín<sup>a</sup>

M Isabel González <sup>a</sup>

Nuria Holgado<sup>a</sup>

Ana I Jimenez<sup>a</sup>

Nuria Ortega<sup>a</sup>

Isabel Page<sup>a</sup>

Alba Parrado <sup>a</sup>

María Pérez<sup>a</sup>

Lydia Blanco-Peris<sup>a</sup>

<sup>a</sup> Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

**Corresponding author:** M Carmen Martín; <u>cmartinalo@saludcastillayleon.es;</u> Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

# Sources of research support

This work has been supported by Roche Diagnostics International Ltd., who provided free equipment and test reagents. Roche Diagnostics International Ltd. was not involved, either in study design, collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.

1

# 2 Acknowledgements

LB and MCM conceived and designed the study, NH, NO; MP and AP acquired data,
IP, AJ and MIGF performed analysis and interpretation of laboratory data, MCM and
LB drafted the article and revised it critically for important intellectual content, all
authors provided final approval of the version to be submitted.

7 The authors thank to all blood donors making this work possible by allowing
8 research use of their samples by the Biobanco del Centro de Hemoterapia y
9 Hemodonación de Castilla y León. They also thank the staff in charge of blood
10 donation, and lab technicians for their efforts and Roche for its support.

# 11 Ethical considerations

This study was conducted according with national regulations, institutional policies and in the tenets of the Helsinki Declaration. This study was approved by the Valladolid Health Area Drug Research Ethics Committee, in a meeting held on June 11, 2020 with the reference number "BIO-2020-93". Included donors consented to participate in Biobank research activities. The privacy rights of human subjects were always observed.

# Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors

#### 18 Abstract

19 Background and objectives: COVID-19 can either cause death or go unnoticed but antibodies will remain protecting us of SARS-CoV-2 reinfection for an 20 21 uncertain time and to a uncertain extent. Knowledge of COVID-19 22 epidemiological and hematological features should help make a good forecast of 23 resources for possible future outbreaks or vaccination strategies, and would 24 facilitate decisions in the social sphere by a more reliable estimate of the 25 percentage of immunized individuals. Our aim was to describe seroprevalence 26 evolution from summer 2019 to autumn 2020 in Spain and to determine its 27 relationship with age, blood group or haematological parameters.

Materials and methods: Sera and plasma from historical donation archives were randomized and a total of 12,718 samples tested by a Chemiluminiscent analysis for anti SARS-CoV-2 N protein total immunoglobulins. Blood donors were 60.9% males, average age 46+/-13. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings.

**Results:** 6.7% donors were positive by the end of 1st wave. No differences by sex, age or blood group were found regarding antibodies. Leukocyte and neutrophil counts were lower (p<0.001) and haemoglobin was lower (p<0.001) in positive donations than in negative ones. Sex differences were found in neutrophils, leukocytes, haemoglobin and haematocrit as related to SARS-CoV-2 antibodies.

40 **Conclusions:** Seroprevalence due to asymptomatic cases would be slightly 41 lower than the overall one due to age restrictions for blood donors. Sex and age

42	would not affect COVID-19 susceptibility but its severity. Gender differences
43	would be present in asymptomatic individuals. Further studies are needed to
44	confirm these gender differences as they can help better understand the immune
45	response to COVID-19, its pathogenesis and prognosis.

46

Keywords: COVID-19, antibodies, immunity, seroprevalence, SARS-CoV-2

# 47 Abbreviations

Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM); polymerase chain reaction (PCR); standard deviation (SD); interquartile range (IQR); White blood cells (WBC), haemoglobin (Hb), haematocrit (HCT), mean corpuscular volume (MCV).

#### 48 Introduction

Most SARS-CoV-2 infection cases develop an effective immune response during 49 50 infection. Even these who curse asymptomatic or with just mild symptoms mount 51 humoral or cell responses. This makes it hard to calculate accurate infection or 52 fatality rates and prevalence [1]. Immunization either due to infection or to vaccination leads to viral eradication and to specific T cell responses and 53 antibodies against SARS-CoV-2, that usually peak 8-15 days after infection [2]. 54 55 Antibodies that neutralize the virus are the primary protection against COVID-19, 56 and lymphocyte responses augment protection.

57 Antibody assays are quite different: they either detect antibodies against different 58 viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG, 59 IgM, IgA or their combinations. It should be noticed that every approved vaccine 60 in Europe to date (May 2020) enhances anti-S responses, whereas an infection 61 leads to a multi specific response to SARS-CoV2 antigens. To make it even 62 messier, many factors can influence test performance, including cross-reactivity 63 with other coronaviruses or platform (laboratory-based vs point-of-care, lateral 64 flow). Chemiluminiscence assays have suitable performances regarding both 65 sensibility and sensitivity while correlation to neutralizing antibodies would be 66 around 0.7 [3].

Our region, Castilla y Leon, with a population of 2.299.598 inhabitants, has 67 68 accumulated nearly 225.000 COVID-19 confirmed cases 69 (https://analisis.datosabiertos.jcyl.es/), with an overall case-fatality rate of 3.01 to date. Our institution, Centro de Hemoterapia de Castilla y León keeps within its 70 Biobank plasma samples from every single donation along the last ten years, that 71 72 makes up around one million samples. Any demographic data such as sex or age 73 and laboratory parameters (blood counts, blood group, haemoglobin, etc....) is as well kept in a database (Hemasoft, eDelphyn). 74

75 Blood donor-based serosurveillance is a powerful and cost-effective strategy to 76 monitor infectious diseases. There are quite a lot of infections for which routine 77 donor screening is well known to be useful, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-78 lymphotrophic virus (HTLV), and West Nile virus (WNV) [1], babesiosis or 79 Crimea-Congo fever. The use of blood donor samples means we're sampling 80 81 mainly asymptomatic and recovered cases of COVID-19 (normal blood donation is allowed after 28 days following COVID-19 symptoms' resolution). 82

Seroprevalence surveys are then needed to monitor coronavirus pandemic, both before and after vaccination strategies [4]. Reported COVID-19 cases do not represent the full SARS-CoV-2 disease burden due to low detection rates, especially at the beginning of pandemics. Case reports are dependent on patients' seeking health care, massive local screenings or regional tracking activities. Analysis of data from seroprevalence and serosurveillance is a

common strategy for estimating underreporting and real disease burden. There 89 are several features that should be taken into account, including time between 90 infection and antibody development or antibody waning, which must be 91 92 considered to understand seroprevalence surveys avoiding biases. Any seroprevalence survey should be evaluated for selection bias. Serological 93 94 surveys with a random sampling design of the general population are difficult to 95 perform in a pandemic, but a random sampling design of the general population 96 yields a seroprevalence estimate least likely to be affected by selection bias. 97 Blood donors are a quite representative subset of general population aged 18-65 98 and our historical plasma collection was big enough to perform a time-layered 99 randomization.

Heterogeneity of susceptibility and transmission is hard to evaluate but does exist 100 101 [5]. A portion of the population is not susceptible to infection from the first 102 pathogen contact. Some of them may have pre-existing immunity via cross-103 reactivity or particular host factors such as mucosal immunity or trained innate 104 immunity protection (as it has been reported to be conferred by DTP or BCG 105 vaccination)[6]. There is as well a proportion of seronegative individuals that will 106 develop immunity by T cell mediated responses but without exhibiting an 107 antibody response [7].

108 The starting hypothesis is the existence of a certain number of asymptomatic carriers of the SARS-CoV-2 virus that would develop antibodies against it [7] (and 109 subsequently contribute to herd immunity). Those asymptomatic cases were 110 unnoticeable before testing began and might had been circulating from an 111 unknown moment. Early cases have been described in France [8], arising the 112 113 question of whether the pathogen could have been circulating even before the 114 official recording of the first cases.-The main aim of this study was to determine what percentage of the population has had contact with SARS-CoV-2 at different 115

times and has therefore developed antibodies against it. A secondary goal was to describe haematological features of seropositive donors and establish whether sex, age, blood group or haematological abnormalities were related COVID-19 exposure.

120 Knowledge of COVID-19 epidemiological and hematological features should help 121 make a good forecast of resources for possible future outbreaks or vaccination 122 strategies, and would facilitate decisions in the social sphere by a more reliable 123 estimate of the percentage of immunized individuals.

## 124 MATERIAL and METHODS

## 125 Aim, design and setting of the study

The aim of this study was to analytically obtain, a reliable knowledge of asymptomatic COVID-19 cases and their immunological and haematological characteristics, seroprevalence, rate of positive donations and its temporal evolution along the first wave in Spain. So, a retrospective observational analysis was performed.

#### 131 Participants

The Biobank is included in the National Registry of Biobanks (RD17 / 16/2011) with the number B.0000264. The institution holds an ISO 9001: 2015 certification endorsing our granting of safety and traceability of any human biological sample we distribute, always behaving Spanish and European rules on human samples and data protection management.

The study population comprised randomised plasma-EDTA and serum frozen samples from blood, plasma (excluding convalescent) and platelet donations from July 2019 to October 2020. Donations collected since 19/07/2019 (week -24) to 19/10/2020 (week 43) were randomized to select a minimum of 150

141 donations per week. A total of 12,718 samples of 11,444 donors over 18 years142 old were included.

143 Laboratory data and analyses

All haematological and demographic data were extracted from electronic
database eDelphyn (Hemasoft). Variables analyzed included age, sex, blood
group, and laboratory data.

Major laboratory markers were extracted from our donation database. Routine
blood examinations included leukocyte (WBC), neutrophil, lymphocyte, platelet,
monocyte, eosinophil and basophil counts (cells\*10<sup>3</sup>/µL) and their percentages.
Serum immunoglobulins IgG, IgA and IgM (mg/dL), haemoglobin (Hb),
haematocrit (HCT) and corpuscular mean volume were analysed as well.

152 An automated chemiluminiscence double-antigen sandwich immunoassay for the 153 in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human serum and plasma was performed. The target antigen of this immunoassay is a 154 recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 (Roche, 155 156 Basel, Switzerland) detects antibodies correlating with virus-neutralizing ones and is therefore useful to help characterize the immune reaction to SARS-CoV-2 157 [9, 10]. Immunoassay was validated by our serology lab by testing of 6 pairs of 158 samples (plasma EDTA and serum) from diagnosed PCR-positive, symptomatic 159 160 cases infected by mid-April, that were previously reported positive by the Spanish National Microbiology Centre, and checked to be as well positive for IgG 161 162 (Chemiluminiscence, N protein, Abbott Alinity S, Chicago USA) and IgA (ELISA, S protein, Euroimmunn, Lübeck, Germany) antiSARS-CoV-2. Another set of ten 163 164 prepandemic samples, therefore supposed to be negative, were equally analyzed. A 100% concordance was yielded by these validation assays. The cut-165 off was that recommended by manufacturer (OD>1 to report reactivity). 166 167 Researchers performing anti SARS-CoV-2 analyses were blind to the condition of

168 COVID-19 convalescence and to any other characteristic of the donors or to the169 donation dates.

170 Statistical analysis

Demographic and clinical characteristics of patients are expressed as their mean and standard deviation (SD) for continuous variables and frequency distributions are reported for categorical variables. Age was analysed both as continuous and categorical variable; in the latter case was recoded into 4 groups: <30, 30-45, 45-60, 60-75 years old.


Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality. Only IgG and IgM serum levels followed normal distributions, therefore non-parametric Mann-Whitney U test was performed to compare laboratory values. To contrast the hypothesis of independence within categorical variables, Pearson's Chi-square and Fisher's exact test were carried out. All tests were calculated with a confidence level of 0.05.

182 Results

A total of 12,718 randomized donations (either whole blood, plasmapheresis or platelet apheresis) were tested for total anti SARS-CoV2 antibodies. Donors made up 11,444, 60.91% males, aged 18-75, average 46+/-13, 45.8% A, 40.3% O, 10.56% B, 3.31% AB.

Seropositivity rate grew up from week 11 to week 25, reaching a 11.1% peak, with just subtle descents until week 43 when 2<sup>nd</sup> wave arose in our country. Plateau was reached by the last week of May 2020, 11 weeks after close lockdown in Spain (that begun in March, 15<sup>th</sup>) and 17 weeks after 31/01, the date of the first declared case in or country. 660 out of 9,886 single donors were positive within weeks 11 to 43, that makes a seroprevalence of 6.73% at the end of the first wave.

Three 2019 donations were reactive (from July, September and October) but none of them were positive when testing separately IgG, IgA or IgM. Their ODs were 1.05, 1.08 and 5.46 respectively. 1,142 donations from year 2019 were analyzed.



198

Figure 1. COVID-19 seropositive donation rate 2020 evolution by weeks. Temporal
 series' model (mobile median t=6; exponential smoothing model R[2]=0.991;p<0.001)</li>

201 No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of

202 donors were found (Table 1).

	Neg	ative	Pos	sitive
	n	%	n	%
Female	4531	38.1%	164	40.3%
Male	7375	61.9%	243	59.7%
<30	3551	29.8%	104	25.6%
30 to 45	5036	42.3%	180	44.2%
45 to 60	1151	9.7%	42	10.3%
60 to 75	2168	18.2%	81	19.9%
А	5411	45.5%	198	48.6%
AB	423	3.6%	16	3.9%
В	919	7.7%	22	5.4%
0	5151	43.3%	171	42.0%

Table 1. Sex. age range and blood group of positive/negative anti SARS-COV2 donations

Immunoglobulin levels didn't show any differences as comparing positive and negative donations. Haemoglobin (14.9 vs 14.7 g/dL; p<0.001) and haematocrit (45.2% vs 44.4%;p<0.001) were both significantly lower in positive donations . Leukocyte count (WBC) was as well slightly lower (7.23 vs 7.06 cells\*10<sup>3</sup>/µL; p=0.026) (Table 2). A trend was found of lower number of neutrophils (4.3 vs. 4.2 cells\*10<sup>3</sup>/µL; p=0.117), lower count of monocytes (0.46 vs. 0.45 cells\*10<sup>3</sup>/µL; p=0.117) and higher percent of basophils (0.49% vs 0.51%; p=0.131).

212 As layering data by sex (Table 3), the fact arose that haematocrit (46.8% vs 213 45.9%; p<0.001) and haemoglobin (15.5 vs 15.3 g/dL; p<0.001) were significantly 214 lower just in males and that positive females had significantly less WBC (7.67 vs 215  $cells*10^{3}/\mu L; p=0.027)$ and neutrophil 7.25 numbers (4.53 vs 4.27 216 cells\*10<sup>3</sup>/ $\mu$ L;p=0.014).

217 Some trends were found as well related to sex. Regarding positive women neutrophil percent would be lower (59.4% vs 58.10% p=0.065), with a higher 218 219 lymphocyte percent (31.7% vs 33.10%; p=0.074) a lower platelet count (261 vs 220 255 cells\*10<sup>3</sup>/µL; p=0.152), monocyte count (0.46 vs 0.44 cells\*10<sup>3</sup>/µL; p=0.132) 221 and basophil percent (0.5% vs 0.4%; p=0.060). Anaemia was more frequent in 222 positive male donors as (6.1% vs 9.6%; p=0.031), A trend of. No other significant 223 differences were found either in males, females or overall. Figure 2 summarize 224 these findings.

	Overall	Male	Female
Hb	4	$\mathbf{V}$	-
Hematocrite	•	+	-
Leukocyte count	4	-	$\mathbf{\Psi}$
Platelet count	-	-	$ \Psi $
Neutrophil count	•	-	$\mathbf{\Psi}$
Neutrophil %	-	-	1
Lymphocyte count	-	-	$\mathbf{\Psi}$
Lymphocyte %	-	-	$\mathbf{\Psi}$
Monocyte count	4	-	$\mathbf{\Psi}$
Basophil %	1	-	$\mathbf{\Psi}$

225

Figure 2. Haematological features in SARS-CoV-2 positive donations. Intensecoloured arrows represent significant differences. Light-coloured arrows represent statistical trends.

# 229 Discussion

230 A slightly lower seroprevalence than that found in general population was found among blood donors without COVID-19 antecedents. The 6.73% seroprevalence 231 we found is a little lower than that reported in the seroprevalence study ENE-232 233 COVID-19 promoted by the Instituto Nacional the Epidemiología [11], where it is reported that a 7.2% of the participants in our region would have anti SARS-234 CoV2 IgG antibodies by the end of June 2020. Almost one guarter people in our 235 region (25.51% according to National Institute of Statistics, INE 2020 data) is 236 237 older than 65 and elderly are necessarily underrepresented in this study as it 238 comprises blood donors. That happens as well with population aged less than 18 (under 4.5% in our region). One limitation of this study is that of age, restricted to 239 240 18-75 years old, but it would make just a little difference of 0.5% in 241 seroprevalence estimation. Immunization rate would be a bit higher regarding the 242 fact that some individuals do not exhibit antibodies but still mount an efficient 243 specific T-cell response [2]

Perhaps the main strength of our study is the large number of samples we randomized and tested along almost one year. The first recorded COVID-19 case in Spain was reported on 31/01/2020, but 3 positive donations were found as testing samples collected along 2019. That could be meaningful in two opposite ways: one possible explanation would be cross reactivity to seasonal cold coronaviruses and the other would be that SARS-CoV-2 might have been circulating at least since 2019 summer.

251 It is now known that up to 28% people would have protection against SARS-CoV-2 due to cross reaction to other coronaviruses [2]. It has been checked that long-252 term cross-reactive both T-cell and antibodies can be a correlate of protections 253 against COVID-19 [12].Asymptomatic or mild cases couldn't be diagnosed or 254 255 reported until the first tests were developed in the first term of 2020. There are other reports about SARS-CoV-2 circulating in Europe along 2019. Italy's Ministry 256 of Health reported high levels of unusual strains of flu and pneumonia 257 concentrated in the area around Milan and appearing in 17 of Italy's 20 regions 258 259 [13]. Our three 2019 positive donors would be even earlier cases, but the simplest explanation would be that of cross reaction. In fact, we cannot 100% 260 ascertain whether some of the positives along the period of study might be cross 261 reactions as well or both reactive due to SARS-CoV-2 infection together with 262 263 previous coronavirus immunity.

264 Conversely to clinical forms of COVID-19 [14,15] neither age nor sex have an 265 influence on the probability to develop an asymptomatic COVID-19 infection in 266 our cohort. Several smaller seroprevalence reports from European countries 267 support this feature [16-20]. It may be therefore ascertained that age and sex do 268 not have a role in SARSCoV-2 infection susceptibility, but only in their 269 progression to severe forms. 270 Blood group has been reported elsewhere [7,21-23] to confere susceptibility or determine severity of SARS-CoV2 infection. Most studies do not separate 271 272 susceptibility and severity. It should be noticed that there are no large studies 273 characterizing asymptomatic cases in literature, perhaps this is one of the reports 274 comprising more asymptomatic individuals. Relationship of ABO system with susceptibility is not supported by our data. We excluded convalescent plasma 275 276 donors, opposite to other studies, that focused into these asymptomatic positive 277 donors [22]. Perhaps blood group might be related only to symptomatic cases 278 and would be therefore related to severity but not related to asymptomatic SARS-279 CoV-2 infection. Another surface antigens such as HLA or KIR might be as well involved and should be studied. 280

281 Several blood count anomalies have been reported to be associated to SARS-282 CoV2 infection, notably lymphopenia and neutrophilia are related to severest 283 forms [24]. Our data conversely reveal that asymptomatic positive women had a significant lower count of WBC and neutrophils as compared to negative ones. 284 285 Similar low counts of WBC and neutrophils have been reported in young (<19) 286 cohorts, comprising mainly mild and asymptomatic cases [25]. Perhaps this 287 feature might be therefore a correlate of mildness. Elevation of monocytes have been elsewhere reported in short series of mild cases [26]. Our observation in will 288 289 be in the same line of those findings but a gender bias cannot be discarded so far 290 seropositive women would go in the opposite direction.

Several reports about haemolytic anaemia secondary to SARSCoV-2 have been published [27-30]. We cannot discard the possibility of a mild silent haemolytic anaemia in asymptomatic cases. Again, little analysis of asymptomatic cases is available by the moment.

295 We can conclude that seroprevalence estimations through blood donation 296 analysis resemble data obtained from population-based surveys. Sex and age 297 would not affect COVID-19 susceptibility but its severity. Gender differences are 298 present even in asymptomatic individuals: females are known to develop milder 299 COVID-19, this fact might be related to a lower WBC count whereas positive 300 males although asymptomatic, present anaemia more frequently than negative ones. Further studies in large cohorts are needed to confirm these gender 301 302 differences and to characterize asymptomatic COVID-19 cases as they can help 303 better understand immune response to COVID-19, its pathogenesis and 304 prognosis.

# 305 Availability of data and materials

- 306 The data that support the findings of this study are not openly available due to reasons
- 307 of sensitivity and are available from the corresponding author upon reasonable request
- 308 and after mandatory approval of proposals by the Valladolid Este Ethical Committee
- 309
- 310

# 311 References

- Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory
   Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood
   Donor Populations. Clin Infect Dis. 2020;72(2):254-256
- Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020 Oct 1;183(1):158-168.e14. doi: 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PMID: 32979941; PMCID: PMC7427556.
- Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys
   HB, van der Schoot E. Evaluation of SARS-CoV-2 antibody titers and
   potency for convalescent plasma donation: a brief commentary. Vox Sang.
   2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23.
   PMID: 33368373.
- Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections,
   Symptomatic Infections, Hospitalizations, and Deaths Using
   Seroprevalence Surveys. JAMA Netw Open. 2021;4(1):e2033706

- Friston K, Costello A, Pillay D. 'Dark matter', second waves and
   epidemiological modelling. *BMJ Glob Health*. 2020;5(12):e003978
- 330 6. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care
  331 providers and the protection against COVID-19. *J Clin Invest.*332 2021;131(2):e145545
- Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, Candon S,
  Fafi-Kremer S. Intrafamilial Exposure to SARS-CoV-2 Associated with
  Cellular Immune Response without Seroconversion, France. Emerg Infect
  Dis. 2021;27(1):113–21
- 337 8. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X.
  338 Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O
  339 French blood donors. *Antiviral Res.* 2020;181:104880
- 340
  9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol.* 2020;129:104480
- 343 10. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2
  344 serological assays in a high-prevalence setting [published online ahead of
  345 print, 2021 Feb 3]. *Eur J Clin Microbiol Infect Dis*. 2021;1-9
- 11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk
  for SARS-CoV-2 in community dwelling population of Spain: nationwide
  seroepidemiological study. *BMJ*. 2020;371:m4509
- 349 12. Poonia B, Kottilil S. Immune Correlates of COVID-19 Control. Front
   350 Immunol. 2020;11:569611
- 351 13. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in
  352 emergency departments as a COVID-19 surveillance system: a time series
  353 study. BMJ Open. 2021;11(2):e044388.
- 354 14. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C355 reactive protein, and lymphocytes as key clues from a multicentre retrospective
  356 study. Immun Ageing. 2020;17:22
- Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The age again in the eye of the COVID-19 storm: evidence-based decision making.
  Immun Ageing. 2021 May 20;18(1):24. doi: 10.1186/s12979-021-00237-w.
  PMID: 34016150; PMCID: PMC8134808.

361

- 362 16. Dickson E, Palmateer NE, Murray J, et al. Enhanced surveillance of COVID363 19 in Scotland: population-based seroprevalence surveillance for SARS364 CoV-2 during the first wave of the epidemic. *Public Health*. 2021;190:132365 134
- 366 17. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in
  367 Brazil: results from two successive nationwide serological household
  368 surveys. *Lancet Glob Health*. 2020;8(11):e1390-e1398.

- 369 18. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey
   370 of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. Euro
   371 Surveill. 2020;25(31):2001369
- 372 19. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community
  373 Seroprevalence of SARS-CoV-2 Antibodies Two Georgia Counties, April
  374 28-May 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(29):965-970
- 375 20. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS376 CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a
  377 population-based study. *Lancet*. 2020;396(10247):313-319
- 378 21. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood
  379 Types and COVID-19: Spurious, Anecdotal, or Truly Important
  380 Relationships? A Reasoned Review of Available Data. *Viruses*.
  381 2021;13(2):160
- 382 22. Muñiz-Diaz E, Llopis J, Parra R, et al. Relationship between the ABO blood
   383 group and COVID-19 susceptibility, severity and mortality in two cohorts
   384 of patients. *Blood Transfus*. 2021;19(1):54-63
- 23. Zalba Marcos S, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA. 385 Infection and thrombosis associated with COVID-19: Possible role of the ABO 386 387 blood group. Infección y trombosis asociada a la COVID-19: posible papel del sanguíneo ABO. Med (Barc). 2020;155(8):340-343. 388 grupo Clin 389 doi:10.1016/j.medcli.2020.06.020
- 390 24. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From
   391 cytopenia to coagulopathy. *Eur J Haematol*. 2020;105(5):540-546
- 392 25. Toba N, Gupta S, Ali AY, ElSaban M, Khamis AH, Ho SB, Popatia R. COVID-19
   393 under 19: A meta-analysis. Pediatr Pulmonol. 2021 Jun;56(6):1332-1341. doi:
   394 10.1002/ppul.25312. Epub 2021 Feb 25. PMID: 33631060; PMCID: PMC8013606
- 395 26. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of Non-Classical and Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection.
  397 Cytometry A. 2020 Sep;97(9):887-890. doi: 10.1002/cyto.a.24188. Epub 2020 Aug 14. PMID: 32654350; PMCID: PMC7404377
- 399 27. Gruden G, Beggiato E, Camerino E, Capriotti S, Canepa S, Scandella M,
  400 Avolio M, Pittalunga F, Barutta F, Durazzo M. Treatment with eltrombopag
  401 of severe immune thrombocytopenia and hemolytic anemia associated
  402 with COVID-19 pneumonia: a case report. Ther Adv Hematol. 2021 Apr
  403 27;12:20406207211011353. doi: 10.1177/20406207211011353. PMID:
  404 33995989; PMCID: PMC8082984.
- 405 28. Liput JR, Jordan K, Patadia R, Kander E. Warm Autoimmune Hemolytic
  406 Anemia Associated With Asymptomatic SARS-CoV-2 Infection. Cureus.
  407 2021 Mar 25;13(3):e14101. doi: 10.7759/cureus.14101. PMID: 33927918;
  408 PMCID: PMC8075761.
- 409 29. Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ,
  410 Iyadurai R. Evans syndrome and immune thrombocytopenia in two
  411 patients with COVID-19. J Med Virol. 2021 May;93(5):2642-2644. doi:

412 10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID:
413 PMC8013600.

- 30. Mausoleo A, Henriquez S, Goujard C, Roque-Afonso AM, Noel N,
  Lambotte O. Severe IgA-mediated autoimmune hemolytic anemia
  triggered by SARS-CoV-2 infection. Leuk Lymphoma. 2021 Feb 22:1-5. doi:
  10.1080/10428194.2021.1888378. Epub ahead of print. PMID: 33618609.
- 418 31. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving
  419 Reactive Oxygen Species and Myeloperoxidase Explains Clinical
  420 Deterioration and Fatality in COVID-19. Int J Biol Sci. 2021 Jan 1;17(1):62421 72
- 422 32. Dattilo M. The role of host defences in Covid 19 and treatments
  423 thereof. *Mol Med.* 2020;26(1):90
- 424

425

# 426 Tables

		n	mean	median	SD	IQR
Age	Negative	11906	44.0	45.8	12.8	34.2-54.2
	Positive	407	44.2	46.5	13.0	32.8-54.8
IgA	Negative	194	236.9	223.5	101.3	163-292
	Positive	5	224.4	274.0	92.3	134-282
IgG	Negative	194	1065.4	1037.5	217.4	910-1185
	Positive	5	1123.8	1095.0	249.9	924-1229
IgM	Negative	194	113.3	100.5	64.8	69-138
-	Positive	5	103.0	89.0	41.7	78-97
WBC (p=0.026)	Negative	9759	7.4	7.2	1.8	6.13-8.49
· ·	Positive	346	7.2	7.1	1.6	6.11-8.12
Hb (p<0.001)	Negative	11218	14.9	14.9	1.3	14-15.8
	Positive	386	14.7	14.7	1.2	13.8-15.4
Hematocrite						
(p<0.001)	Negative	11218	45.1	45.2	3.5	42.7-47.6
	Positive	386	44.5	44.4	3.5	42.3-46.6
Platelets	Negative	11217	247.9	243.0	54.3	211-280
	Positive	386	247.3	242.5	55.7	206-276
Neutrophil count	Negative	11217	4.4	4.3	1.4	3.44-5.19
(p=0.117)	Positive	386	4.3	4.2	1.2	3.34-5.03
Neutrophil %	Negative	11217	58.8	58.9	7.5	53.8-63.9
	Positive	386	58.5	58.7	7.1	54.3-63.4
Lymphocyte	NT /	11016	0.0	• •	07	1.06.0.70
count	Negative	11216	2.3	2.3	0.7	1.86-2.72
<b>T 1</b> ( 0)	Positive	386	2.3	2.2	0.6	1.89-2.64
Lymphocyte %	Negative	11216	31.7	31.5	6.9	27-36.2
Monocyte count	Positive	386	32.1	32.4	6.6	27.3-36.1
(p=0.131)	Negative	11216	0.5	0.46	0.1	0.38-0.56
_	Positive	386	0.5	0.46	0.1	0.37-0.54
Monocyte %	Negative	11216	6.5	6.4	1.5	5.5-7.4
·	Positive	386	6.5	6.4	1.4	5.5-7.3
Eosinophil count	Negative	11217	0.2	0.2	0.1	0.09-0.23
-	Positive	386	0.2	0.1	0.1	0.09-0.22
Eosinophil %	Negative	11217	2.5	2.1	1.8	1.3-3.2
-	Positive	386	2.4	2.0	1.7	1.3-3.1
Basophil count	Negative	11217	0.0	0.0	0.0	0.02-0.04
*	Positive	386	0.0	0.0	0.0	0.02-0.04
Basophil %	Negative	11217	0.5	0.5	0.2	0.3-0.6
-	Positive	386	0.5	0.5	0.3	0.4-0.6

427 Table 2. Descriptive analysis of age. immunoglobulins (mg/dL). Hb(g/dL), hemogram

428 counts (cells\*10[3]/µL) and percentages of reactive and non-reactive donations

			n	mean	median	SD	IQR
Age	Female	Negative	4531	42.0	43.50	13.3	30.3-53.3
-		Positive	164	42.1	45.39	13.6	28.6-53.1
	Male	Negative	7375	45.2	46.81	12.2	36.7-54.8
		Positive	243	45.7	46.98	12.5	35.5-55.9
IgA	Female	Negative	54	214.3	200.00	97.0	157-250
C		Positive	3	235.3	274.00	105.5	116-316
	Male	Negative	140	245.6	233.50	101.9	176.5-302.5
		Positive	2	208.0	208.00	104.7	134-282
IgG	Female	Negative	54	1076.4	1062.50	191.3	964-1186
0		Positive	3	1082.7	1095.00	152.9	924-1229
	Male	Negative	140	1061.2	1029.00	227.2	903-1181.5
		Positive	2	1185.5	1185.50	436.3	877-1494
IgM	Female	Negative	54	143.1	129.50	64.6	94-169
-9		Positive	3	114.3	89.00	53.7	78-176
	Male	Negative	140	101.8	90.00	61.3	64.5-121
		Positive	2	86.0	<b>86.00</b>	15.6	75-97
MCV	Female	Negative	3618	91.2	91.50	4.8	88.4-94.4
	i cinulo	Positive	142	91.2	91.40	4.1	88.9-93.5
	Male	Negative	6141	90.9	91.40 91.00	4.6	88.1-93.8
	Whate	Positive	204	90.5 90.6	91.00 91.00	4.8	88-94.1
WBC	Female*	Negative	3618	7.8	7.69	1.9	6.49-9
WDC	remate	Positive	142	7.4	7.21	1.5	6.27-8.26
	Male	Negative	6949	7.2	7.02	1.8	5.99-8.2
	Iviale	Positive	229	7.1	6.98	1.6	6.01-8.03
Hb	Female	Negative	4269	13.8	13.80	0.9	13.2-14.4
по	Female	Positive	4209		13.80	0.9	13.2-14.4
	Male*			13.7			
	Male*	Negative	6949	15.5	15.50 15.20	1.0	14.9-16.2
UCT	г 1	Positive	229	15.3	15.30	1.0	14.7-15.8
HCT	Female	Negative	4269	42.4	42.30	2.7	40.6-44
		Positive	157	42.1	42.00	2.5	40.5-43.6
	Male*	Negative	6949	46.8	46.80	2.8	45-48.6
		Positive	229	46.2	45.90	3.0	44.3-47.7
PLT	Female	Negative	4268	265.9	261.00	56.6	228-300
	(t)	Positive	157	261.0	255.00	60.5	219-296
	Male	Negative	6949	236.8	233.00	49.6	204-266
NI( 1.1		Positive	229	237.9	234.00	50.2	203-266
Neutrophil count	Femala*	Negative	4268	4.7	4.53	1.4	3.65-5.47
count		Positive	4208	4.7 4.4	4.55 4.27	1.4	3.56-5.08
	Male	Negative	6949	4.4 4.3		1.2 1.4	3.36-3.08
	wiate	U U			4.10 4 10		
Neutrophil		Positive	229	4.2	4.10	1.2	3.24-4.97
%	Female	Negative	4268	59.2	59.40	7.4	54.2-64.3
		Positive	157	58.1	59.40 58.10	7.2	54-62.9
			107		20110		2.02.7
	Male	Negative	6949	58.6	58.70	7.5	53.6-63.6

Lymphocyte							
count	Female*	Negative	4267	2.5	2.39	0.7	1.97-2.88
		Positive	157	2.4	2.35	0.6	2.02-2.81
	Male	Negative	6949	2.2	2.18	0.6	1.8-2.62
		Positive	229	2.2	2.17	0.6	1.8-2.51
Lymphocyte				<b>22</b> 0			
%	Female	Negative	4267	32.0	31.70	6.9	27.4-36.5
	(t)	Positive	157	33.0	33.10	7.0	28.4-37
	Male	Negative	6949	31.5	31.30	6.9	26.8-36.1
		Positive	229	31.4	31.70	6.3	26.7-35.6
Monocyte count	Female	Negative	4267	0.5	0.46	0.1	0.37-0.55
count	(t)	Positive	157	0.5	0.40	0.1	0.37-0.55
	Male	Negative	6949	0.5	0.44	0.1	0.30-0.52
	Walt	Positive	229	0.5	0.40 0.47	0.1	0.38-0.50
Monocyte		rosuve	229	0.5	0.47	0.1	0.38-0.33
%	Female	Negative	4267	6.1	6.00	1.4	5.1-6.9
		Positive	157	6.1	6.00	1.4	5.2-6.9
	Male	Negative	6949	6.7	6.60	1.5	5.7-7.6
		Positive	229	6.7	6.70	1.4	5.8-7.6
Eosinophil							
count	Female	Negative	4268	0.2	0.14	0.1	0.09-0.21
		Positive	157	0.2	0.13	0.1	0.09-0.19
	Male	Negative	6949	0.2	0.16	0.1	0.1-0.24
		Positive	229	0.2	0.15	0.1	0.09-0.23
Eosinophil			10 50		4.00		
%	Female	Negative	4268	2.2	1.80	1.6	1.2-2.8
		Positive	157	2.3	1.80	1.7	1.1-2.8
	Male	Negative	6949	2.7	2.20	1.8	1.4-3.4
D 1.1		Positive	229	2.5	2.10	1.7	1.4-3.2
Basophil	Famala	Nagativa	4268	0.0	0.03	0.0	0.02-0.05
count	Female	Negative Positive	4208	0.0	0.03	0.0	0.02-0.05
	Mala		6949	0.0	0.04	0.0	0.02-0.03
	Male	Negative Positive			0.03		
Decorb:10/	Eamola		229	0.0	0.03	0.0	0.02-0.04
Basophil %	Female (t)	Negative	4268	0.5		0.2	0.3-0.6
	(t) Mala	Positive Nogetive	157	0.5	0.50	0.3	0.3-0.6
	Male	Negative	6949 220	0.5	0.50	0.2	0.3-0.6
		Positive	229	0.5	0.50	0.2	0.4-0.6

430 \*p<0.01

431 (t) p<0.2

432 Table 3. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), MCV,

433 hemogram counts (cells\* $10[3]/\mu L$ ) and percents, of reactive and non-reactive donations

434 by sex.

435

436